Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors

Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors

Activation of immune checkpoint pathways and limited T- cell infiltration result in immunological escape of tumors. Although immune checkpoint inhibitors are currently approved for several types of cancers, the response rate is often limited by the lack of tumor specific T-cells within the malignant...

Full description

Bibliographic Details
Main Authors: S. Feola, C. Capasso, M. Fusciello, B. Martins, S. Tähtinen, M. Medeot, S. Carpi, F. Frascaro, E. Ylosmäki, K. Peltonen, L. Pastore, V. Cerullo
Format: Article
Language:English
Published: Taylor & Francis Group 2018-08-01
Series:OncoImmunology
Subjects:
breast cancer
cancer epitopes
cancer vaccines
checkpoint inhibitors
immunotherapy
melanoma
oncolytic vaccines
oncolytic viruses
therapeutic antibodies
therapeutic vaccination
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1457596

Internet

http://dx.doi.org/10.1080/2162402X.2018.1457596

Similar Items